Industry
Biotechnology
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Loading...
Open
16.48
Mkt cap
22M
Volume
6.1K
High
16.83
P/E Ratio
-0.89
52-wk high
22.32
Low
16.10
Div yield
N/A
52-wk low
6.20
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 11:42 am
Portfolio Pulse from Avi Kapoor
July 24, 2024 | 6:37 pm
Portfolio Pulse from Avi Kapoor
July 24, 2024 | 5:26 pm
Portfolio Pulse from Avi Kapoor
July 24, 2024 | 4:30 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:52 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:47 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:40 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:35 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 11:48 am
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 10:42 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.